Be the first to know

Never miss an update from Biogen. Did you know that during reporting season, the announcements from NASDAQ:BIIB often move the market?

Biogen (NASDAQ:BIIB) Company Logo

By joining StockLight, you agree to our Terms & Conditions and Privacy Policy
Create Alert Follow BIIB

Biogen (BIIB)

US NASDAQ:BIIB (37.5B)

241.305
-2.45 (-1.02%)
10:05am EST
LOADING
Loading price chart..

Summary

Current Price: $241.31
52w High/Low: $236.26 - 355.63
Market Cap: 37.5B
Price/Earnings: 7.97
Dividend Yield: -
Volume/Average: 156K - 3M
Biogen (NASDAQ:BIIB) Company Logo
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide... More
Biogen (NASDAQ:BIIB) Company Logo

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. Biogen was founded in 1978 in Geneva by several prominent biologists, including Kenneth Murray of the University of Edinburgh, Phillip Allen Sharp of the Massachusetts Institute of Technology, Walter Gilbert of Harvard , Heinz Schaller, University of Heidelberg and Charles Weissmann, University of Zurich . Gilbert and Sharp were subsequently honored with Nobel Prizes: Gilbert was recognized in 1980 with the Nobel Prize in Chemistry for his work in understanding DNA sequencing, while Sharp received the Nobel Prize in Physiology or Medicine in 1993 for his discovery of split genes.

Annual Reports

Biogen (BIIB) 10-K Annual Report Feb 6th 2020
2020
(219kb)
Biogen (BIIB) 10-K Annual Report Feb 6th 2019
2019
(255kb)
Biogen (BIIB) 10-K Annual Report Feb 1st 2018
2018
(217kb)
Biogen (BIIB) 10-K Annual Report Feb 2nd 2017
2017
(2.4mb)
Biogen (BIIB) 10-K Annual Report Feb 3rd 2016
2016
(2.4mb)

Dividend History

No dividends found.

Quantitative Ratios

Stock Ratios Locked
You viewed 3 companies today
Ratios will be unlocked
again tomorrow or;

Unlock these ratios,
configure alerts
and much more...

Download StockLight

All Ratios, Alerts and other features are available in our iOS and Android apps:
Download on iOS Download on Android

We are working on updating this web app to fully enable Quantitative Ratios. All other current web features including annual reports, price sensitive announcements, dividends and earnings transcripts are free to use here on our web app.
Not enough data to calculate ratios

Company News

2 Bargain Stocks You Can Buy Right Now
November 19th, 2020 - Motley Fool

They're dirt cheap compared to their peers. David Jagielski The price at which you buy a stock can greatly affect your overall returns. While you don't necessarily want to wait forever for a stock to fall to a price where you think it's cheap enou...

3 Best Biotech Stocks to Buy in November
November 18th, 2020 - Motley Fool

While most investors are watching the companies working to end the COVID-19 crisis, take a moment to consider three that are continuing the fight against an even more stubborn disease. Jason Hawthorne Often, the best investments are the ones most ...

Does Good News About Biogen's Alzheimer's Drug Mean Bad News for Rivals?
November 12th, 2020 - Motley Fool

Biogen's Alzheimer's disease drug, aducanumab, got positive news from the FDA last week. If the drug is approved, what does that mean for other companies with prospective Alzheimer's drug candidates? Jim Halley Shares in Biogen (NASDAQ:BIIB) were ...

Biogen's Possible Shopping List: 3 Companies the Biotech Might Buy
November 11th, 2020 - Motley Fool

This biotech titan should be a top player on the merger and acquisition scene next year. George Budwell Biogen (NASDAQ:BIIB) might be in deep trouble. The biotech's core multiple sclerosis franchise has been hit hard by generic competition this ye...

Why Warren Buffett's Riskiest Bet in Years Is on the Brink of Bombing
November 11th, 2020 - Motley Fool

The odds appear to be heavily against this Berkshire investment paying off. Keith Speights Our experts issued a rare "Double Down" Buy alert on this one stock... Learn more.Warren Buffett isn't exactly viewed as a big gambler. Sure, the Oracle of ...

Every Stock Tells a Story
November 9th, 2020 - Motley Fool

Beyond numbers. Motley Fool Staff In this episode of Rule Breaker Investing, Motley Fool co-founder David Gardner is joined by Motley Fool analysts Karl Thiel, Rick Munarriz, and Tim Beyers, to share stories about some interesting stocks and how t...

Why Biogen Stock Is Tanking Today
November 9th, 2020 - Motley Fool

The biotech's high-profile Alzheimer's disease drug candidate appears to be headed for a rejection. George Budwell Biotech heavyweight Biogen (NASDAQ:BIIB) saw its shares sink by as much as 32% in pre-market trading Monday. The biotech's stock is ...

FDA Committee Votes Strongly Against Biogen's Alzheimer's Disease Drug
November 6th, 2020 - Motley Fool

The committee of outside experts saw right through the FDA's cheerleading. Brian Orelli, PhD After a long day of the Food and Drug Administration and Biogen (NASDAQ:BIIB) arguing that Biogen's Alzheimer's disease drug, aducanumab, should be approv...